Show simple item record

dc.contributor.authorBeland, FA
dc.contributor.authorChurchwell, MI
dc.contributor.authorHewer, A
dc.contributor.authorPhillips, DH
dc.contributor.authorda Costa, GG
dc.contributor.authorMarques, MM
dc.date.accessioned2018-09-11T10:20:14Z
dc.date.issued2004-07-23
dc.identifier2
dc.identifier.citationBIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 320 pp. 297 - 302
dc.identifier.issn0006-291X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2627
dc.identifier.doi10.1016/j.bbrc.2004.05.168
dc.description.abstractThe nonsteroidal antiestrogen tamoxifen increases the risk of endometrial cancer; however, the mechanism for the induction of these tumors is not known. Recently, Sharma et a]. [Biochem. Biophys. Res. Commun. 307 (2003) 157], using high performance liquid chromatography (HPLC) with online postcolumn photochemical activation and fluorescence detection, reported the presence of (E)-alpha-(deoxyguanosin-N-2-yl)tamoxifen in DNA from human endometrial explants incubated with tamoxifen. Inasmuch as the methodology used by these investigators does not allow unambiguous characterization of tamoxifen-DNA adducts, we have used two additional techniques (HPLC coupled with electrospray ionization tandem mass spectrometry and P-32-postlabeling analyses) to assay for the presence of tamoxifen-DNA adducts in the human endometrial explant DNA. Tamoxifen-DNA adducts were not detected by either method. (C) 2004 Elsevier Inc. All rights reserved.
dc.format.extent297 - 302
dc.languageeng
dc.language.isoeng
dc.publisherACADEMIC PRESS INC ELSEVIER SCIENCE
dc.titleAnalysis of tamoxifen-DNA adducts in endometrial explants by MS and P-32-postlabeling
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/j.bbrc.2004.05.168
rioxxterms.licenseref.startdate2004-07-23
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
pubs.notesaffiliation: Beland, FA (Reprint Author), Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA. Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA. Inst Canc Res, Sutton SM2 5NG, Surrey, England. Univ Tecn Lisboa, Ctr Quim Estrutural, Inst Super Tecn, P-104900 Lisbon, Portugal. keywords: tamoxifen; P-32-postlabeling; HPLC; electrospray ionization tandem mass spectrometry; DNA adducts; endometrial cancer keywords-plus: BREAST-CANCER PREVENTION; TRIALS; WOMEN; GENOTOXICITY; CULTURE research-areas: Biochemistry & Molecular Biology; Biophysics web-of-science-categories: Biochemistry & Molecular Biology; Biophysics author-email: [email protected] researcherid-numbers: Marques, M. Matilde/E-2535-2012 orcid-numbers: Marques, M. Matilde/0000-0002-7526-4962 Phillips, David/0000-0001-8509-3485 Beland, Frederick/0000-0002-2113-6260 number-of-cited-references: 24 times-cited: 15 usage-count-last-180-days: 0 usage-count-since-2013: 2 journal-iso: Biochem. Biophys. Res. Commun. doc-delivery-number: 836PJ unique-id: ISI:000222567700003 da: 2018-09-10
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Human Biomonitoring & Carcinogen Activation
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Human Biomonitoring & Carcinogen Activation
pubs.volume320
pubs.embargo.termsNot known
icr.researchteamHuman Biomonitoring & Carcinogen Activationen_US
dc.contributor.icrauthorPhillips, David Hunteren


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record